Virios Therapeutics (VIRI) Competitors $2.32 -0.10 (-4.13%) (As of 12/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends VIRI vs. KYTX, IPHA, ACTU, CRBP, HURA, DRUG, STRO, SGMT, CRBU, and TSVTShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Kyverna Therapeutics (KYTX), Innate Pharma (IPHA), Actuate Therapeutics (ACTU), Corbus Pharmaceuticals (CRBP), TuHURA Biosciences (HURA), Bright Minds Biosciences (DRUG), Sutro Biopharma (STRO), Sagimet Biosciences (SGMT), Caribou Biosciences (CRBU), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Kyverna Therapeutics Innate Pharma Actuate Therapeutics Corbus Pharmaceuticals TuHURA Biosciences Bright Minds Biosciences Sutro Biopharma Sagimet Biosciences Caribou Biosciences 2seventy bio Virios Therapeutics (NASDAQ:VIRI) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings. Is VIRI or KYTX more profitable? Kyverna Therapeutics' return on equity of -51.12% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Kyverna Therapeutics N/A -51.12%-37.91% Do analysts recommend VIRI or KYTX? Virios Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 29.31%. Kyverna Therapeutics has a consensus price target of $25.71, indicating a potential upside of 542.86%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer VIRI or KYTX? In the previous week, Kyverna Therapeutics had 39 more articles in the media than Virios Therapeutics. MarketBeat recorded 39 mentions for Kyverna Therapeutics and 0 mentions for Virios Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.09 beat Virios Therapeutics' score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Kyverna Therapeutics Neutral Do insiders and institutionals hold more shares of VIRI or KYTX? 9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor VIRI or KYTX? Kyverna Therapeutics received 7 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Kyverna Therapeutics an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% Kyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% Which has preferable valuation and earnings, VIRI or KYTX? Virios Therapeutics has higher earnings, but lower revenue than Kyverna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-8.59Kyverna Therapeutics$7.03M24.56-$60.37MN/AN/A SummaryKyverna Therapeutics beats Virios Therapeutics on 12 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.68M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-8.5910.5991.3417.19Price / SalesN/A195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book11.605.104.794.78Net Income-$5.30M$151.51M$120.07M$225.60M7 Day Performance-1.69%-2.15%-1.89%-1.24%1 Month Performance-14.39%-3.14%11.45%3.36%1 Year Performance300.69%11.50%30.61%16.58% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$2.32-4.1%$3.00+29.3%+287.1%$44.68MN/A-8.595KYTXKyverna Therapeutics2.4246 of 5 stars$4.20-5.0%$25.71+512.2%N/A$181.32M$7.03M0.0096News CoverageIPHAInnate Pharma2.7604 of 5 stars$2.22-26.6%$11.50+419.1%-23.5%$179.38M$24.85M0.00220News CoverageGap DownHigh Trading VolumeACTUActuate TherapeuticsN/A$9.00+4.4%N/AN/A$175.79MN/A0.0010Gap UpCRBPCorbus Pharmaceuticals3.8067 of 5 stars$14.42-4.4%$62.00+330.0%+147.6%$175.64M$880,000.00-3.2240HURATuHURA BiosciencesN/A$4.14-16.0%$15.00+262.3%N/A$175.06MN/A0.00N/AAnalyst ForecastNews CoverageDRUGBright Minds Biosciences3.5821 of 5 stars$39.31-4.1%$75.00+90.8%+2,621.8%$174.30MN/A-60.29N/ANews CoverageSTROSutro Biopharma4.4638 of 5 stars$2.10-0.9%$11.13+429.8%-51.3%$173.17M$153.73M-1.32240SGMTSagimet Biosciences2.3237 of 5 stars$5.60+27.6%$23.00+310.7%-8.0%$171.75M$2M0.008Gap UpHigh Trading VolumeCRBUCaribou Biosciences2.2043 of 5 stars$1.87-2.1%$10.20+445.5%-69.4%$169.33M$11.48M-1.16100Positive NewsTSVT2seventy bio2.2124 of 5 stars$3.26-0.3%$9.00+176.1%-7.1%$168.18M$100.39M-1.76440Positive News Related Companies and Tools Related Companies Kyverna Therapeutics Alternatives Innate Pharma Alternatives Actuate Therapeutics Alternatives Corbus Pharmaceuticals Alternatives TuHURA Biosciences Alternatives Bright Minds Biosciences Alternatives Sutro Biopharma Alternatives Sagimet Biosciences Alternatives Caribou Biosciences Alternatives 2seventy bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts